腹部脂肪溶解 | Abdominal Lipolysis

Note: This product is not available for sale to Brazil. Residents from Brazil will not be able to check out this item as there's no shipping arrangement available.

腹部脂肪溶解(瘦腰) 顯著進程:約2-4個月

肥胖，尤其是腹部肥胖，與心血管疾病、癌症和全因死亡率新增有關[1]。雖然BMI現在被認為是一種臨床或流行病學工具，用於評估一級和二級預防中的心血管風險，但一些研究仍然表明BMI不是死亡率風險的良好預測名額[2,3]。肥胖相關的共病與腹部肥胖和內臟脂肪堆積的關係比與全身脂肪量的關係更為密切[4]。普通人群中的VAI可作為間接反映心臟代謝風險的標誌物[5,6]。

多學科研證復康組合:

• 藥物及其他醫療方案,請遵從醫生建議
• 飲食營養請依營養師指引
• 運動及或心理輔導,請參考各專家建議
• 為免錯誤診斷及漏診,請上傳最近一個月醫院的專業診斷報告

不適合使用:

• 多囊卵巢綜合征（PCOS）引起的肥胖
• 藥物引起的水腫(例如類固醇)
• 對該組合的成份有過敏
• 胃潰瘍

腹部脂肪溶解(瘦腰)組合: (1個月試用份量)

1. 醇脂膽酸 X3
2. 螯合研究 X2
3. 酶素研究 X1
4. 參碱蜂膠液 X3

生活配合:

• 每天稍快步行活動量不少於8000步,輕微出汗較理想
• 戒夜宵習慣
• 女士耍戒食高雌激素食物儘量不要吃
• 早睡早起,不要熬夜

飲食戒口:

• 高雌激素食物: 雞皮、雞翅膀、雞油、魚生刺身、魚子、燕窩、雪蛤膏、當歸、牛奶等等
• 甜味飲料儘量不要喝
• 碳水化合物、高脂食物適量減少(30%-50%)

注意：

• 本品為營養補充品，不能代替藥物。
• 懷孕或哺乳期女士、嬰幼兒，請不要食用本品。
• 如不瞭解問題原因或問題持續，請儘快諮詢醫生。

Abdominal lipolysis (thin waist) Significant progress: about 2-4 months

Obesity, especially abdominal obesity, is associated with increased cardiovascular disease, cancer and all-cause mortality [1]. Although BMI is now considered as a clinical or epidemiological tool to assess cardiovascular risk in primary and secondary prevention, some studies still show that BMI is not a good predictor of mortality risk [2,3]. Obesity related comorbidities are more closely related to abdominal obesity and visceral fat accumulation than to the amount of body fat [4]. VAI in the general population can be used as a marker indirectly reflecting the risk of cardiac metabolism [5,6].

Rehabilitation combination of multi-disciplinary scientific research certificate:

• Please follow your doctor's advice on drugs and other medical options
• Please follow the dietitian's guidelines for diet and nutrition
• For sports and or psychological counseling, please refer to the suggestions of experts
• To avoid misdiagnosis and missed diagnosis, please upload the professional diagnosis report of the hospital in the latest month

Not suitable for use:

• Obesity caused by polycystic ovary syndrome (PCOS)
• Drug induced edema (e.g. steroids)
• Allergic to the ingredients of the combination
• Gastric ulcer

Abdominal lipolysis (lean waist) combination: (Trial portion for 1 month)

Life cooperation:

• The daily walking activity is not less than 8000 steps, and slight sweating is ideal
• Quit the night snack habit
• Women try not to eat high estrogen foods
• Go to bed early and get up early. Don't stay up late

Dietary abstinence:

• High estrogen foods: chicken skin, chicken wings, chicken oil, sashimi, roe, bird's nest, snow clam paste, Angelica sinensis, milk, etc
• Try not to drink sweet drinks
• Carbohydrates and high-fat foods decreased moderately (30% - 50%)

Warm Reminder:

• This product is a nutritional supplement and cannot replace drugs.
• Pregnant or lactating women, infants and young children, please do not eat this product.
• If you do not know the cause of the problem or the problem persists, please consult your doctor as soon as possible.

Refs參考文獻:

1. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women.Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB Circulation. 2008 Apr 1; 117(13):1658-67.
2. Cause-specific excess deaths associated with underweight, overweight, and obesity.Flegal KM, Graubard BI, illiamson DF, Gail MH JAMA. 2007 Nov 7; 298(17):2028-37.
3. Should we continue to use BMI as a cardiovascular risk factor? Franzosi MG Lancet. 2006 Aug 19; 368(9536):624-5.
4. Blüher S, Molz E, Wiegand S, Otto KP, Sergeyev E, Tuschy S, L'Allemand-Jander D, Kiess W, Holl RW, Adiposity Patients Registry Initiative and German Competence Net Obesity.J Clin Endocrinol Metab. 2013 Aug; 98(8):3384-93.
5. Visceral adiposity index, hypertriglyceridemic waist and risk of diabetes: the China Health and Nutrition Survey 2009. Du T, Sun X, Huo R, Yu X Int J Obes (Lond). 2014 Jun; 38(6):840-7.
6. New obesity indices and adipokines in normotensive patients and patients with hypertension: comparative pilot analysis.Stepien M, Stepien A, Banach M, Wlazel RN, Paradowski M, Rizzo M, Toth PP, Rysz J Angiology. 2014 Apr; 65(4):333-42.

本產品並非根據《藥劑業及毒藥條例》或《中醫藥條例》注册。 任何對其提出的索賠均不受此類登記評估的約束。 本產品不用於診斷、治療或預防任何疾病。